Cardiovascular disease expected to place $1 trillion cost burden on US

pharmafile | February 20, 2017 | News story | Medical Communications, Sales and Marketing cardiovascular disease 

A study conducted by RTI International, a non-profit research institute, has warned that the US could have to balance over $1.1 trillion in costs due the rise of cardiovascular disease by 2035. The research found that nearly half of all US citizens will suffer from some incidence of cardio vascular disease in just less than two decades time.

RTI had previously conducted a study, in 2011, that vastly underestimated the issues facing cardiovascular health. The early report had suggested that 100 million Americans would suffer from cardiovascular disease by 2030; unfortunately, that prediction came true only four years later. The study found that by age 45, cardiovascular disease risk sits at 50% and this increases to 80% by age 65.

“Mostly driven by the aging of the population, the prevalence and costs of cardiovascular disease are expected to increase significantly in the next 20 years with total costs reaching over a $1.1 trillion by 2035,” said Olga Khavjou, economist in RTI’s public health economics program and lead author of the study.

Currently, the cost to the economy of the US has increased to $555 billion, in 2016. A heavy burden that is predicted to increase to the trillions and risk of incidence is expected to triple in those aged over 80 years old whilst doubling in those between 65-79 years old. The report also finds that a higher proportion of black Americans and Hispanics will be vulnerable to the disease. In terms of numbers, 45% of the total population of the US is expected to be effected by cardiovascular disease – rising to 131.2 million in total.

RTI International has recommended three measures to help address the issue facing the US: increase funding for heart and stroke research by the National Institutes of health; enhanced focus on prevention to improve and preserve population health from birth to old age, and preservation and expansion of access to high-quality affordable health care.

Parts of the methods for prevention are blood pressure and cholesterol screenings, smoking cessations services and behavioural counselling for obesity.

Ben Hargreaves

Related Content

Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease

On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s …


Eli Lilly’s Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients

Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy …


Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 …

Latest content